The biomaterials refer to manmade substances that can be utilized to support tissues or structures in the body. These are natural or synthetic materials that are used in medical applications to support, enhance, or replace damaged tissue or a biological function. The main types of biomaterials are metallic biomaterial, polymeric biomaterials, natural biomaterials and ceramics. The metallic biomaterials are stainless steels, titanium alloys, and cobalt alloys used to provide internal support to biological tissues. The metallic biomaterials are manmade systems that are utilized in joint replacements, dental implants, orthopedic fixations, and stents to offer internal support to biological tissues. Biomaterials have a wide application in cardiovascular, orthopedic, ophthalmology, dental, plastic surgery, wound healing, tissue engineering and neurological/central nervous system and are used in hospitals and clinics, ambulatory surgical centers and other end users. The biomaterials market research report is one of a series of new reports from The Business Research Company that provides biomaterials market statistics, including biomaterials industry global market size, regional shares, competitors with a biomaterials market share, detailed biomaterials market segments, market trends and opportunities, and any further data you may need to thrive in the biomaterials industry. This biomaterials market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global biomaterials market size grew from $104.36 billion in 2022 to $119.95 billion in 2023 at a compound annual growth rate (CAGR) of 14.9%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The biomaterials market size is expected to grow to $219.79 billion in 2027 at a CAGR of 16.3%. The rising incidence of cardiovascular diseases is driving the growth of the biomaterials market. Cardiovascular disorders are caused by high blood pressure, smoking, high cholesterol, inactivity, and other factors. The increase in the prevalence of cardiovascular disorders is mainly due to noncontagious diseases like diabetes, chronic respiratory illness, and heart attacks due to hypertension. Biomaterials such as heart valves, cardiopulmonary bypass system, stents, vascular grafts, complete artificial heart, and pacemakers are used as a healing mechanism for damaged and diseased heart tissue. For instance, in October 2022, according to a report shared by The Centers for Disease Control and Prevention, a US-based national public health agency, the main cause of death in the United States for men, women, and members of the majority of racial and ethnic groups is heart disease. In the United States, heart disease caused approximately 697,000 fatalities in 2020, or one death out of every five. In the United States, a cardiovascular disease death occurs every 34 seconds. Therefore, the rising incidence of cardiovascular diseases will increase the demand for biomaterials. The strategic partnership is a key trend gaining popularity in the biomaterials market. Key companies are focusing on partnerships to develop new implants and combination devices based on biomaterials by leveraging each other’s expertise, technology, and resources. These partnerships are also focused on enhancing the adoption of biomaterials. Such partnerships enable companies to gain a competitive edge in the market and increase revenue. For instance, in December 2020, DuPont, a US-based producer of biomaterials, partnered with a Finland-based global chemicals company, Kemira Oyj, for development and commercialization of new breakthrough biomaterials. In the partnership, Kemira's role would be to jointly develop and market a variety of novel biobased and biodegradable goods across Kemira's major product lines. As per the conditions of the partnership, Kemira will have access to the engineered polysaccharide platform, a novel and distinctive biomaterial technology from DuPont. Through this partnership, the two parties will soon be able to sell a variety of novel, biobased, and biodegradable products in their respective core industries. In January 2021, Evonik Industries AG, a German specialty chemicals company acquired the LACTEL business of biodegradable polymers from DURECT Corporation for $15 million. With this acquisition, Evonik aims to expand in fast-growing markets such as biomaterials for tissue engineering, advanced drug delivery, and the 3D printing of implantable medical devices. DURECT Corporation is a US-based specialty pharmaceutical company. Major players in the biomaterials market are Carpenter Technology Corporation, Corbion NV, Evonik Industries, Royal DSM, Berkeley Advanced Biomaterials, BASF SE, Zimmer Biomet, Johnson and Johnson, Invibio, Medtronic, Organogenesis Holdings Inc., Stryker, Wright Medical Group NV, 3M Healthcare, AdvanSource Biomaterials Corporation, Baxter, Covestro, Cam Bioceramics BV, Celanese Corporation, CoorsTek Inc., CeramTec, Victrex plc and Collagen Matrix Inc., North America was the largest region in the biomaterials market in 2022. The regions covered in the biomaterials market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the biomaterials market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The biomaterials market consists of sales of metals, polymers, and composites. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global biomaterials market is segmented - 1) By Type: Metallic Biomaterial, Polymeric Biomaterials, Natural Biomaterials, Ceramics 2) By Application: Cardiovascular, Orthopedic, Ophthalmology, Dental, Plastic Surgery, Wound Healing, Tissue Engineering, Neurological/Central Nervous System 3) By End Use: Hospitals And Clinics, Ambulatory Surgical Centers, Other End Users

Orthopedic biomaterials are materials intended to be inserted into the human body as constituents of devices designed to perform certain biological functions by either substituting or repairing various tissues, such as bones, cartilage, ligaments, tendons, and others. The orthopedic biomaterials market covered in this report is segmented by material type into ceramics and bioactive glasses, calcium phosphate cement, polymers, metal, and composites. Polymers are used as orthopedic biomaterials intended to be inserted into the human body as constituents. The various applications are orthopedic implants, joint replacement/reconstruction, bio-resorbable tissue fixation, orthobiologics, and viscosupplementation. These are used by various end-users such as hospitals, clinics, and others. The orthopedic biomaterials market research report is one of a series of new reports from The Business Research Company that provides orthopedic biomaterials market statistics, including orthopedic biomaterials industry global market size, regional shares, competitors with a orthopedic biomaterials market share, detailed orthopedic biomaterials market segments, market trends and opportunities, and any further data you may need to thrive in the orthopedic biomaterials industry. This orthopedic biomaterials market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global orthopedic biomaterials market grew from $16.9 billion in 2022 to $18.62 billion in 2023 at a compound annual growth rate (CAGR) of 10.2%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The orthopedic biomaterials market is expected to grow from $29.69 billion in 2027 at a CAGR of 12.4%. The rise in the incidence of musculoskeletal disorders is expected to drive the orthopedic biomaterials market. According to the World Health Organization (WHO) report, musculoskeletal conditions are the leading contributor to disability worldwide. About 20-33% of the population suffer from a musculoskeletal disability. Musculoskeletal disorders induce fractures, swelling, and discomfort in the joints, ligaments, and tendons that cause movement disabilities. The burden of musculoskeletal conditions is known to increase with age. The sustainable development goals (SDGs) and the Decade of Healthy Ageing 2020–2030 have called for increased global attention and action on musculoskeletal health. Biomaterials are used to treat these disorders. Hence, the incidence of musculoskeletal disorders is projected to drive the orthopedic biomaterials market. The high cost of conducting clinical trials is expected to hinder the biomaterials market growth. The orthopedic biomaterials are directly implanted in the body. Therefore, it is important to prove the safety and biocompatibility of these materials. However, the high cost of conducting clinical trials is acting as a major roadblock. The clinical studies are expensive and time-consuming due to the number of tests required, and the length of each test. The investment of resources, time, and funding grows with successive stages. Additional costs are associated with the result of the trials at different phases. For instance, the cost of a failed phase 3 trial is not just the cost associated with the trial itself but the cost of all prior trials as well as the cost of lost time pursuing a potentially viable alternative or repeating the steps. Therefore, the high cost of conducting clinical trials is expected to impact the orthopedic biomaterials market. 3D printing of orthopedic implants is one of the recent developments in the orthopedic biomaterials market. 3D printing technology is used to produce a large range of medical equipment, such as those with complicated structures or characteristics to suit a patient’s particular anatomy. 3D printing of orthopedic implants enables the design of more natural anatomical shapes, as well as the design of porous bone replacement scaffolds that can be easily integrated into the design of the implant. This allows natural bone regeneration to generate higher reliability of the implant. 3D printing of orthopedic implants is a trend in the orthopedic biomaterial market that is attracting many players. For instance, Evonik, a Germany-based chemical company has invested in Meditool, a Chinese-based 3d printed implant start-up that produces models and implants by using polyether ketone (PEEK) polymer supplied by Evonik. In November 2020, Olympus, a Japanese medical technology company, acquired FH Ortho for an undisclosed amount. The acquisition would help Olympus to grow in the field of orthopaedic minimally invasive surgery. FH Ortho is a France based orthopaedics company. Major players in the orthopedic biomaterials market are Zimmer Biomet Holdings Inc., Stryker Corporation, Victrex PLC (Invibio Ltd.), Globus Medical Inc., CAM Bioceramics B.V., Heraeus Holding GmbH, Exactech Inc., Collagen Matrix Inc., Evonik Industries AG, and Koninklijke DSM N.V. (DSM Biomedical B.V.). North America was the largest region in the orthopedic biomaterials market in 2022. Western Europe was the second largest region in the global orthopedic biomaterials market report. The regions covered in the global orthopedic biomaterials market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the orthopedic biomaterials market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The orthopedic biomaterials market consists of sales of glass-ceramic and bioactive glasses and calcium phosphate cements. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global orthopedic biomaterials market is segmented - 1) By Material Type: Ceramics & Bioactive Glasses, Calcium Phosphate Cements, Polymers, Metal, Composites 2) By Application: Orthopedic Implants, Joint Replacement/Reconstruction, Bio-Resorbable Tissue Fixation, Orthobiologics, Viscosupplementation 3) By End-User: Hospitals, Clinics, Other End-Users

Implantable drug delivery devices are drug delivery systems implanted under the skin that transmit drugs into the bloodstream from a reservoir. These devices facilitate site specific drug delivery and require smaller doses, thereby minimising side effects. The main products of implantable drug delivery devices is contraceptive implants, spinal implants, brachytherapy seeds, drug-eluting stents, bioabsorbable stents, intraocular stents, infusion pumps, and others. Spinal implants are devices that are used by surgeons while performing surgery to treat deformity, stabilise and strengthen the spine, and facilitate fusion. The technologies involved are diffusion, osmosis, magnetic, and others. The various applications involved are contraception, ophthalmology, cardiovascular, diabetes, oncology, autoimmune diseases, and others. The implantable drug delivery devices market research report is one of a series of new reports from The Business Research Company that provides implantable drug delivery devices market statistics, including implantable drug delivery devices industry global market size, regional shares, competitors with a implantable drug delivery devices market share, detailed implantable drug delivery devices market segments, market trends and opportunities, and any further data you may need to thrive in the implantable drug delivery devices industry. This implantable drug delivery devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global implantable drug delivery devices market grew from $18.35 billion in 2022 to $19.58 billion in 2023 at a compound annual growth rate (CAGR) of 6.7%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The implantable drug delivery devices market is expected to grow from $26 billion in 2027 at a CAGR of 7.3%. The rise in the incidence of target diseases such as diabetic retinopathy, cancer, cardiovascular diseases, and other chronic diseases is expected to drive the implantable drug delivery devices market. According to the International Diabetes Federation (IDF), the global prevalence of diabetic retinopathy was one in three in 2020. Implantable drug delivery devices are used for site-specific drug administration where the drug is most needed, such as Gliadel® wafer as an implant used in the treatment of brain tumors, Lupron depot for the treatment of prostate cancer. Hence, the site-specific drug administration nature of implantable drug devices, which help in the treatment of target diseases, is driving the implantable drug delivery devices market. The rising number of product recalls and lawsuits associated with implantable drug delivery devices is expected to hinder the market. In the past few years, there had been an increase in product recalls and lawsuits connected with these devices. For instance, in June 2022, Medtronic plc recalled Cobalt XT, Cobalt, and Crome Implantable Cardioverter Defibrillators (ICDs) and Cardiac Resynchronization Therapy Defibrillators (CRT-Ds) for the reasons of reports of devices with a short circuit protection (SCP) alert resulting in reduced-energy electric shock delivery, instead of delivering a second phase of high voltage therapy. This may result in failure of device and irregular heartbeat which can lead to more serious issues. Therefore, the rising number of product recalls and lawsuits concerning implantable drug delivery devices is expected to hinder the growth of the market. Companies and researchers are focusing on developing 3D implantable drug delivery devices. 3D printed titanium transcutaneous ports are implanted behind the patient's ear, allowing healthcare professionals to access the catheters. For instance, in February 2020, Renishaw and Herantis Pharma announced the award-winning device, which received positive results in phase 2 trials, that consists of up to four catheters implanted in the relevant brain areas. Researchers at King Abdullah University of Science and Technology have introduced a miniaturized drug delivery system suitable for in-vivo biomedical applications. The system consists of an electrolytic pump, which operates a micro bellows membrane as an actuator for delivery through microneedles. A two-photon 3D printing technique was used to make a reservoir equipped with a microneedle. In February 2022, Second Sight Medical Products, a California-based manufacturer of prosthetic devices, merged with Nano Precision Medical. The companies would collaborate to develop drug delivery medical implants.Nano Precision Medical is a US-based developer of NanoPortal drug implant technology. Major players in the implantable drug delivery devices market are Allergan Inc., Bayer HealthCare, Medtronic Inc., Nucletron, Boston Scientific Corporation, Abbott Laboratories, Bausch and Lomb Inc., Merck, Genetech Inc., and Psivida. North America was the largest region in the implantable drug delivery devices market in 2022. Asia-Pacific was the second-largest region in the global implantable drug delivery devices market report. The regions covered in the global implantable drug delivery devices market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the implantable drug delivery devices market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The implantable drug delivery devices market consists of sales of contraceptive implants, spinal implants, brachytherapy seeds, drug-eluting stents, bio-absorbable stents, intraocular stents, infusion pumps, and others. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organisations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the chain or as part of other products. The global implantable drug delivery devices market is segmented - 1) By Product: Contraceptive Implants, Spinal Implants, Brachytherapy Seeds, Drug-Eluting Stents, Bio-absorbable Stents, Intraocular Stents, Infusion Pumps, Other Applications 2) By Technology: Diffusion, Osmotic, Magnetic, Other Technologies 3) By Application: Contraception, Ophthalmology, Cardiovascular, Diabetes, Oncology, Autoimmune Diseases, Other Applications

Implantable infusion pumps are drug delivery systems implanted in the patients body that pump the medication into the blood stream in a controlled manner. The implantable infusion pumps market is segmented by type into patient-controlled analgesia (PCA) pumps, enteral pumps, insulin pumps, elastomeric pumps, syringe pumps, and others. The insulin pump is a small device that is put beneath the skin during the operation to deliver insulin in diabetic patients. The various applications of implantable infusion pumps are oncology, pediatrics/neonatology, gastroenterology, hematology, diabetes, and others that are used by hospitals, ambulatory surgical centers, and specialty clinics. The implantable infusion pumps market research report is one of a series of new reports from The Business Research Company that provides implantable infusion pumps market statistics, including implantable infusion pumps industry global market size, regional shares, competitors with a implantable infusion pumps market share, detailed implantable infusion pumps market segments, market trends and opportunities, and any further data you may need to thrive in the implantable infusion pumps industry. This implantable infusion pumps market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global implantable infusion pumps market grew from $18.26 billion in 2022 to $19.14 billion in 2023 at a compound annual growth rate (CAGR) of 4.8%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The implantable infusion pumps market is expected to grow from $23.12 billion in 2027 at a CAGR of 4.8%. The increased prevalence of people with chronic pain, cancer, and diabetes is expected to drive the demand for implantable infusion pumps, as these pumps are commonly used to deliver pharmaceutical drugs during the treatment of these diseases. Chronic illnesses and disorders are on the rise around the world, as the aging population and shifts in social behavior lead to a gradual increase in these diseases. In diseases such as chronic arachnoiditis, which is a condition where one of the membranes surrounding the spinal cord swells, implantable infusion pumps deliver lower dosages of drugs and tend to provide more efficient pain relief. The prevalence of chronic diseases is expected to increase by 57% by 2020, according to the World Health Organization. Therefore, the rise in the prevalence of chronic diseases is expected to drive the growth of the implantable infusion pumps market. The safety concern regarding implantable infusion pumps is a key factor hampering the growth of the implantable infusion pumps market. The magnetic resonance (MR) system can be useful in the diagnosis of a wide range of conditions and diseases, but the MRI setting poses a risk factor for patients with implantable infusion pumps. An MRI examination can influence the programming or functionality of an infusion pump, even if specific requirements have been met. The US food and drug administration received evidence of significant adverse effects including harm to the patient and death associated with the use of implantable infusion pumps in the MR field. Therefore, the safety concerns regarding implantable infusion pumps are expected to limit the growth of the implantable infusion pumps market. Companies in the implantable infusion pump market are increasingly focusing on developing smart infusion pumps. The use of wireless technology in health monitoring devices is increasing, which enhances the ease of usage, connectivity, and data analysis. The integration of wireless technology allows the transfer of data from the device to a smartphone or a wireless device through Bluetooth or cellular connection for data processing and then to display the results, which can be used for further study and to check the health condition of the individual. Software platforms are being developed that allow patient monitoring and reduce human error. In September 2021, Medtronic, a US-based medical device company, acquired implanted infusion pump technology from Alfred E. Mann Foundation. The acquisition is aimed to improve insulin delivery in people with type-1 diabetes. Alfred E. Mann Foundation is a US-based scientific research foundation developing implantable infusion pumps and other medical devices. Major players in the implantable infusion pumps market are Medtronic, Boston Scientific Corporation, Nevro Corporation, Cyberonics, Baxter, B=. Braun Melsungen AG, Fresenius Kabi AG, Smiths Medical, Terumo Corporation, and Neuropace. North America was the largest region in the implantable infusion pumps market in 2022. Asia-Pacific was the second-largest region in the global implantable infusion pumps market. The regions covered in the global implantable infusion pumps market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the implantable infusion pumps market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The implantable infusion pumps market consists of sales of instruments such as patient-controlled analgesia (PCA) pumps, enteral pumps, insulin pumps, elastomeric pumps, syringe pumps, and others. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global implantable infusion pumps market is segmented - 1) By Type: Patient-Controlled Analgesia (PCA) Pumps, Enteral Pumps, Insulin Pumps, Elastomeric Pumps, Syringe Pumps, Other Types 2) By Applications: Oncology, Pediatrics/Neonatology, Gastroenterology, Hematology, Diabetes, Other Applications 3) By End User: Hospitals, Ambulatory Surgical Centers, Specialty Clinics

3D printed implants are artificial devices used to replace a missing or damaged biological structure in the body and are manufactured by laying successive layers of material using inputs from a digital 3D model. The main implantation technologies in 3D printed medical implants are laser beam melting, electronic beam melting, droplet deposition, laminated deposition, and two-photon polymerization. The laser beam melting is a manufacturing process in which 3D components are digitally cut into 2D layers by using a high-performance laser to melt and bond at these points. The various applications include are dental, orthopedic, and craniomaxillofacial that are used by end-users such as medical and surgical centres, pharmaceutical companies, the biotechnology industry, and medical institutions. The 3D printed medical implants market research report is one of a series of new reports from The Business Research Company that provides 3D printed medical implants market statistics, including 3D printed medical implants industry global market size, regional shares, competitors with a 3D printed medical implants market share, detailed 3D printed medical implants market segments, market trends and opportunities, and any further data you may need to thrive in the 3D printed medical implants industry. This 3D printed medical implants market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global 3D printed implants market size will grow from $2.25 billion in 2022 to $2.67 billion in 2023 at a compound annual growth rate (CAGR) of 18.9%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global 3D printed implants market size is expected to grow to $5.36 billion in 2027 at a CAGR of 19.0%. The increasing prevalence of various medical conditions is driving the growth of the 3D printed medical implants market. As the number of people suffering from orthopedic, cardiac, and dental diseases is increasing, the demand for 3D dental crowns, 3D dental bridges, 3D acetabular hip implants, shoulder implants, and various other implants is rising. According to the World Health Organization (WHO), the US had around 65 million people suffering from periodontitis i.e. Inflammation and infection of the ligaments and bones that support the teeth. This mainly occurred due to the rising prevalence of periodontitis, diabetes-related gangrene, osteoarthritis, and peripheral vascular disease. Similarly, the rise in prevalence of other medical conditions is driving the demand for use of 3D printed medical implants. The stringent approval process for the selection of a new material to be used in 3D implants is a time-consuming process that acts as a restraint for the 3D Printed Medical Implants market. 3D Printing requires high-quality materials that should adhere to specific criteria set by regulatory bodies such as US FDA. These regulatory bodies provide procedure guidelines, requirements, and monitor material quality control. For example, the US FDA approved spinal implants made from titanium alloy, but it didn't approve titanium alloy to be used in any other medical device. For each new use of the material, manufacturing companies need to get approval again from regulatory bodies. This causes a lag in the manufacturer's operational cycle and delays the product launch, thus affecting sales and restraining the growth of the 3D printed medical implants market. Many companies in this market are collaborating with various hospitals and rehabilitation centres to provide customizable devices for the specific needs of patients. These collaborations are aimed to be mutually beneficial for both, as the companies can use the network of the hospitals to promote their product and the hospitals would get customizable devices at their convenience. For example, In September 2022, the US Food and Drug Administration (FDA) announced a collaboration with Veterans Health Administration (VHA) to encourage innovation in the 3D medical devices and implants. Similarly, in July 2022, Envista Holdings Corporation announced commercial partnership with dentalcorp Holdings to develop dental implants. The US FDA's Center for Devices and Radiological Health (CDRH) is the regulatory authority for companies that manufacture, repackage, relabel, and/or import medical devices sold in the United States. The medical devices made using 3D printing technology are subject to regulatory requirements before they are marketed (premarket requirements), and also after they are marketed (post-market requirements). FDA classifies 3D printed medical devices into three classes, i.e., Class I, II, and III, with regulatory controls minimum for class I devices and maximum for class III devices. Most class III devices require premarket approval whereas class I devices are exempted from the approval. The manufacturers of 3D printed medical implants are required to establish and follow quality systems to ensure that their products consistently meet applicable requirements and specifications. The manufacturers also need to comply with FDA's standards regarding device design, manufacturing, and testing considerations during the development of 3D printed medical devices. In 2020, Stryker has announced the acquisition of Wright Medical Group N.V., for an undisclosed amount. This acquisition increases Stryker global market position in trauma and extremities, issuing crucial opportunities to advance creativity and reach more patients. Wright Medical Group N.V., is US- based Company is a medical device company focused on extremities and biologics. Major players in the 3D printed medical implants market are 3D Systems Corporations, Stratasys Ltd., Arcam AB, EnvisionTEC, SLM Solutions Group AG, Organovo HoldingsInc., Oxford Performance Materials, Materialise, Cyfuse Biomedical K.K., and Bio3D Technologies. North America was the largest region in the 3D printed medical implants market in 2022. Asia-Pacific was the second-largest region in the global 3D printed medical implants market. The regions covered in the global 3D printed medical implants market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the 3D printed medical implants market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The 3D printed implants market consists of sales of 3D implants created by technologies such as laser beam melting, electronic beam melting, droplet deposition, laminated deposition, and two-photon polymerization. The market value includes the value of related goods sold by the service provider or included within the service offering. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global 3D printed implants market is segmented - 1) By Application: Dental, Orthopedic, Cranio-maxillofacial 2) By End Users: Medical And Surgical Centers, Pharmaceutical Companies, Biotechnology Industry, Medical Institution 3) By Implantation Technology: Laser Beam Melting, Electronic Beam Melting, Droplet Deposition, Laminated Deposition, Two-photon Polymerization

Spine implants are the devices used to correct the deformity in the spine, stabilise and strengthen the spine, and facilitate the fusion of bones in different disorders such as degenerative disc disease, kyphosis, scoliosis, spondylolisthesis, spinal stenosis, and fracture. The main products in the spine implant market are spinal fusion devices, non-fusion devices/motion preservation devices, vertebral compression fracture (VCF) treatment devices, spinal bone stimulators, and spine biologics. The spinal fusion devices provide a solution for spinal instability and are designed specifically to treat spinal disorders. They use surgical procedures to implant titanium-alloy, titanium, stainless steel, and non-metallic devices into the spine. Open surgery and minimally invasive surgery (MIS) are among the procedures involved.The various materials in spine implants include metallic, polymeric, and ceramic. The spinal implants are used in hospitals, specialty orthopaedic and spine centres, and ambulatory surgical centres. The spine implants market research report is one of a series of new reports from The Business Research Company that provides spine implants market statistics, including spine implants industry global market size, regional shares, competitors with a spine implants market share, detailed spine implants market segments, market trends and opportunities, and any further data you may need to thrive in the spine implants industry. This spine implants market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global spine implants market grew from $11.32 billion in 2022 to $12.33 billion in 2023 at a compound annual growth rate (CAGR) of 8.9%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The spine implants market is expected to grow from $16.86 billion in 2027 at a CAGR of 8.1%. The rising incidences of spinal disorders coupled with the usage of minimally invasive surgical procedures are contributing to the growth of the global spinal implants market. According to Branko PRPA, surgical in September 2021, annually there are 1.34 to 4.6 spinal cases per million and 1,400 new cases diagnosed each year, with 33,000 having some type of disability in the US and among them, 30% of the adult female population suffers from lower back pain, compared to 25 percent of the adult male adult population and this is approximately 31% of men acknowledged that their condition affects their employment compared to 20% of women. In 2021, the prevalence of neuropathic pain was found to be between 16% and 55%. And due to the emergence of minimally invasive spine surgical (MISS) approaches, it has now become feasible and efficient for treating a wide range of spinal disorders without long incisions and by avoiding significant damage to muscles surrounding the spine, thereby resulting in fewer post-operative pains and faster recovery. Therefore, the increased prevalence of spinal disorders along with the ease in treatment by MISS approaches is driving the global spinal implants market. The increased treatment procedural cost is acting as a hindrance to the global spinal implants market growth. According to a study published in 2021, approximately 500,000 lumbar spine surgeries were performed in the US. The cost of spinal surgeries has increased by 175% globally and in the US, the annual cost of spine care is estimated at $105 billion per patient annually. Increased treatment procedural costs will increase monetary concerns, limiting the market growth. The innovation of implants in providing minimally invasive and motion-preserving stabilization is a major trend in the spine implants market. For example, RTI Surgical Holdings, a global surgical implant company, has launched the first and only posterior lumbar motion preservation solution, Coflex. Coflex is a differentiated, minimally-invasive, motion-preserving stabilization implant that is FDA PMA-approved for the treatment of moderate to severe lumbar spinal stenosis (LSS). It can be directly implanted following a surgical decompression, without fusing the bones. The device comes in different sizes to fit the patient’s anatomy, and this can be performed even in an outpatient setting. In July 2022, Spineway, a France-based spinal implants manufacturer acquired Spine Innovations for an undisclosed amount. The acquisition would help Spineway to accelerate its innovation and growth and position itself as a leader in this segment. Spinal Innovations is a French manufacturer of spinal implants. Major players in the spine implants market are Medtronic, Depuy Synthes, Johnson & Johnson, Stryker Corporation, NuVasive, Inc., Zimmer Biomet Holdings, Globus Medical, Alphatec Holdings, Orthofix International, and RTI Surgical. North America was the largest region in the spine implants market in 2022. Western Europe was the second largest region in the global spine implants market report. The regions covered in the global spine implants market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the spine implant market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The spine implants market consists of sales of cages, plates, rods values, artificial disc and expandable rods. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organisations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the chain or as part of other products. The global spine implants market is segmented - 1) By Product: Spinal Fusion Devices, Non-Fusion Devices/Motion Preservation Devices, Vertebral Compression Fracture (VCF) Treatment Devices, Spinal Bone Stimulators, Spine Biologics 2) By Procedure: Open Surgery, Minimally Invasive Surgery (MIS) 3) By Material: Metallic, Polymeric, Ceramic 4) By End Use: Hospitals, Specialty Orthopedic And Spine Centers, Ambulatory Surgical Centers

Dental implants are medical devices surgically implanted into the jaw to restore a person's ability to chew or their appearance. The main products of dental implants are tapered implants and parallel walled implants. A tapered implant is a cylindrical implant in which the endosseous part is narrow in diameter towards the apex. The dental implants are made up of materials such as titanium and zirconium that are used by various end-users, such as hospitals and dental clinics. The dental implants market research report is one of a series of new reports from The Business Research Company that provides dental implants market statistics, including dental implants industry global market size, regional shares, competitors with a dental implants market share, detailed dental implants market segments, market trends and opportunities, and any further data you may need to thrive in the dental implants industry. This dental implants market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global dental implants market grew from $6.21 billion in 2022 to $6.86 billion in 2023 at a compound annual growth rate (CAGR) of 10.5%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The dental implants market is expected to grow from $9.85 billion in 2027 at a CAGR of 9.4%. The rising prevalence of dental caries that require dental implants for treatment increase the demand for dental implants. Dental caries is a multifactorial, chronic condition arising from various causes such as nutrition, saliva, micro-organisms, trace minerals, genetic predisposition, and tooth morphology leading to tooth decay. According to a research survey published on BMC healthcare research, an open access research article publisher, in 2021, the prevalence of dental caries in primary and permanent teeth was found to be 41.1% and 68.9% respectively. Dental implants have also become popular as an alternative to removable dentures and are used to replace lost teeth. As a result, the increasing demand for dental implants to replace lost teeth stimulates market growth. The high cost of dental implants is a key factor hampering the growth of the dental implants market. Dental implants are a form of dental surgery that involves multi-stage surgery and are one of the costliest dental procedures to repair false teeth. For instance, dental implants cost an average of between $3,000-$4,500 per tooth in the USA, including total implant size, abutment and crown, and bone graft, which is often needed, cost an additional $200-$3,200. The high cost of dental implants makes them unaffordable for medium and low-income groups obstructing the growth of the dental implants market. Dental implant technology has advanced with the introduction of new technologies and equipment, which improve the consistency and quality of implant treatment. Companies are manufacturing implants that suit the patients’ aesthetics. For instance, in June 2022, ZimVie launched T3 Pro Tapered implant and Encode® Emergence Healing Abutment. The products were designed keeping in mind the products provide both restorative care and aesthetics as well. In 2020, Keystone Dental, a US-based dental implant company, acquired Osteon Medical for an undisclosed amount. This acquisition is providing Keystone with a synergistic sales opportunity to expand in the $5 billion dental implant market. Osteon Medical is an Australia-based company manufacturer of dental implants. Major players in the dental implants market are Zimmer Biomet Holdings Inc., OSSTEM IMPLANT, Institut Straumann AG, Bicon LLC, DENTSPLY Sirona, Danaher Corporation, BioHorizons IPH Inc., Shofu Dental Corporation, Thommen Medical AG, and Ivoclar Vivadent Inc. Asia-Pacific was the largest region in the dental implant market in 2022. Western Europe was the second-largest region in the global dental implant market report. Africa. was the smallest region in the global dental equipment and supplies market. The regions covered in the global dental implants market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the dental implants market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. Dental implants consist of sales of implants such as endosteal implants, subperiosteal implants, and transosteal implants. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organisations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the chain or as part of other products. The global dental implants market is segmented - 1) By Product: Tapered Implants, Parallel Walled Implants 2) By Material: Titanium, Zirconium 3) By End-use: Hospitals, Dental Clinics

Medical equipment are devices that can be instrument, apparatus or machine that can be used in the prevention, diagnosis or treatment of illness or disease, or for detecting, measuring, restoring, correcting or modifying the structure or function of the body for health purpose. The main types of medical equipment are in-vitro diagnostics, dental equipment and supplies, ophthalmic devices, diagnostic imaging equipment, cardiovascular devices, hospital supplies, surgical equipment, orthopedic devices, patient monitoring devices, diabetes care devices, nephrology and urology devices, ENT devices, anesthesia and respiratory devices, neurology devices, and wound care devices. In-vitro diagnostics are tests done on samples like blood or tissue that is taken from the human body. In-vitro diagnostics will detect diseases or other conditions and are used to monitor a person’s overall health to cure, treat, or prevent diseases. The type of expenditure involved is public and private. The various product are instruments/equipment and disposables. The various end users involved are hospitals and clinics, homecare, diagnostics centres, and others. The medical equipment market research report is one of a series of new reports from The Business Research Company that provides medical equipment market statistics, including medical equipment industry global market size, regional shares, competitors with a medical equipment market share, detailed medical equipment market segments, market trends and opportunities, and any further data you may need to thrive in the medical equipment industry. This medical equipment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global medical equipment market grew from $639.75 billion in 2022 to $695.05 billion in 2023 at a compound annual growth rate (CAGR) of 8.6%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The medical equipment market is expected to grow to $922.39 billion in 2027 at a CAGR of 7.3%. The rise in sedentary jobs, busy lifestyles, and changing consumer preferences are affecting the disease profile of the world population, especially non-communicable diseases such as cancer, diabetes, and cardiovascular diseases. Long working hours, less physical activity, and unhealthy eating and drinking habits are major causes of chronic diseases such as diabetes. According to the World Health Organization, chronic disease prevalence is expected to rise by 57% globally, by the year 2020. This is increasing the demand for medical devices used in the diagnosis, prognosis, and treatment of several diseases, thereby driving the demand for medical equipment. These factors are expected to increase the patient pool globally, thereby driving the market during the forecast period. Regulatory changes are likely to lead to increased costs relating to new product development and service offerings to clients. These changes are related to customer data protection such as the European Union's General Data Protection Regulation (GDPR), changes to equipment approval procedures, and other regulatory changes. For instance, according to cookieyed data 2021, in the US, PwC reported that 68% of 200 businesses surveyed intended to spend between $1 million and $10 million to comply with GDPR regulations. The GDPR regulation is an EU law on data protection and privacy of individuals residing in the European Union and the European Economic Area (EEA). It also regulates the export of personal data outside the EU and EEA areas. Additionally, the FDA is requesting more clinical data to support claims, therefore increasing the time to process 510(k)s by over 55% over the last decade. The potential loss of revenue due to delays in product release and additional costs incurred due to stringent approval processes puts a strain on investments relating to new product development, thereby affecting the growth of the medical equipment market. Device performance and patient data are available to healthcare service providers and are helping them to improve patient monitoring and overall care quality. Some companies are integrating medical device data with EMR (Electronic Medical Records) to improve transparency and collaboration. As consumer wearables are becoming more common, patient data volumes are increasing and companies are investing in deploying data management, warehousing, and security technologies. For example, Medtronic launched a tool to augment their cardiac devices to securely transfer device data to doctors and allow them to monitor the critical health indicators of their patients. Major companies in the medical equipment market include Medtronic Inc., Abbott Laboratories, Johnson & Johnson, Cardinal Health, Inc., Becton Dickinson, Siemens AG, STRYKER CORPORATION, Koninklijke Philips N.V., F. Hoffmann-La Roche Ltd., and Boston Scientific Corporation. North America was the largest region in the global medical equipment market in 2022. Asia-Pacific was the second largest region in the global medical equipment market. The regions covered in the medical equipment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the medical equipment market are Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Czech Republic, Denmark, Egypt, Finland, France, Germany, Hong Kong, India, Indonesia, Ireland, Israel, Italy, Japan, Malaysia, Mexico, Netherlands, New Zealand, Nigeria, Norway, Peru, Philippines, Poland, Portugal, Romania, Russia, Saudi Arabia, Singapore, South Africa., South Korea, Spain, Sweden, Switzerland, Thailand, Turkey, UAE, UK, USA, Venezuela, and Vietnam. The medical equipment market consists of sales of devices used in the diagnosis, treatment and monitoring of medical conditions. The market includes diagnostic devices, imaging devices, surgical devices and patient monitoring devices. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global medical equipment market is segmented - 1) By Type: In-Vitro Diagnostics, Dental Equipment And Supplies, Ophthalmic Devices, Diagnostic Imaging Equipment, Cardiovascular Devices, Hospital Supplies, Surgical Equipment, Orthopedic Devices, Patient Monitoring Devices, Diabetes Care Devices, Nephrology And Urology Devices, ENT Devices, Anesthesia And Respiratory Devices, Neurology Devices, Wound Care Devices 2) By Type of Expenditure: Public, Private 3) By Product: Instruments/Equipment, Disposables 4) By End User: Hospitals And Clinics, Homecare, Diagnostics Centers, Other End Users Subsegments Covered: Point-of-Care Diagnostics Devices And Equipment, Immunochemistry Diagnostic Devices And Equipment, Clinical Chemistry Diagnostics Devices And Equipment, Molecular Diagnostics Devices And Equipment, Microbiology Diagnostic Devices And Equipment, Hemostasis Diagnostic Devices And Equipment, Hematology Diagnostic Devices And Equipment, Immunohematology Diagnostic Devices And Equipment, Therapeutic Dental Equipment, General Dental Devices And Equipment, Dental Diagnostic Imaging Devices And Equipment, Dental Surgical Devices And Equipment, Vision Care Devices And Equipment, Cataract Surgery Devices And Equipment, Refractive Surgery Devices And Equipment, Diagnostic And Monitoring Ophthalmic Devices And Equipment, X-Ray Systems Devices And Equipment, Ultrasound Systems Devices And Equipment, Computed Tomography (CT) Scanners Devices And Equipment, Magnetic Resonance Imaging Systems Devices And Equipment, Cardiovascular Monitoring And Diagnostic Devices And Equipment, Nuclear Imaging Devices And Equipment, Cardiovascular Surgery Devices And Equipment, Cardiac Rhythm Management (CRM) Devices And Equipment, Interventional Cardiology Devices And Equipment, Defibrillator Devices And Equipment, Peripheral Vascular Devices And Equipment, Prosthetic Heart Valve Devices And Equipment, Electrophysiology Devices And Equipment, Cardiac Assist Devices And Equipment, Disposable Hospital Supplies, Sterilization Equipment And Disinfectants, Mobility Aids And Transportation Equipment, Operating Room Equipment, Surgical Sutures And Staples, Handheld Surgical Devices And Equipment, Electrosurgical Devices And Equipment, Joint Reconstruction Devices And Equipment, Spinal Surgery Devices And Equipment, Trauma Fixation Devices And Equipment, Orthobiologics Devices And Equipment, Arthroscopy Devices And Equipment, Orthopedic Braces And Support Devices And Equipment, Craniomaxillofacial (CMF) Devices And Equipment, Orthopedic Prosthetics, Orthopedic Accessories,, Fetal And Neonatal Monitoring Devices, Weight Monitoring And Body Temperature Monitoring Devices And Equipment, Vital Parameter Monitoring Devices And Equipment, Remote Patient Monitoring Devices And Equipment, Blood Glucose Test Strips, Insulin Pens, Syringes, Pumps And Injectors, Lancing Devices And Equipment, Continuous Glucose Monitoring Devices And Equipment, Blood Glucose Meters, Dialysis Devices And Equipment, Urinary Stone Treatment Devices And Equipment, Urinary Incontinence & Pelvic Organ Prolapse Devices And Equipment, Benign Prostatic Hyperplasia (BPH) Treatment Devices And Equipment, Endoscopy Devices And Equipment, Hearing Aid Devices And Equipment, Hearing Diagnostic Devices And Equipment, ENT Surgical Devices And Equipment, Hearing Implants, Voice Prosthesis Devices And Equipment, Nasal Splints, Respiratory Devices And Equipment (Therapeutic And Diagnostic), Anesthesia Machines, Anesthesia Disposables, Respiratory Disposables, Cerebrospinal Fluid Management (CSF) Devices And Equipment, Interventional Neurology Devices And Equipment, Neurosurgery Devices And Equipment, Neurostimulation Devices, Traditional Adhesive Dressings, Negative-pressure Wound Therapy (NPWT), Traditional Gauze Dressings, Advanced Wound Care Devices